-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Maintains Overweight on Zevra Therapeutics, Lowers Price Target to $24

Benzinga·11/06/2025 15:00:40
Listen to the news
Cantor Fitzgerald analyst Kristen Kluska maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Overweight and lowers the price target from $29 to $24.